Das nicht kleinzellige Lungenkarzinom (NSCLC) wird meist erst in späten Stadien entdeckt; die Prognose der betroffenen Patienten ist dementsprechend schlecht. In den letzten Jahren konnten entscheidende Fortschritte sowohl in der Diagnostik als auch in der Therapie dieses Tumors verzeichnet werden. So hat sich in den frühen Stadien mittlerweile die adjuvante Therapie etabliert. Beim metastasierten NSCLC steht heute mit den molekular zielgerichteten Substanzen wie dem EGFR-Inhibitor Erlotinib (Tarceva  ) eine effektive und verträgli- 
Summary
Non-small cell lung cancer (NSCLC) usually is diagnosed at an advanced stage. Thus, the prognosis of NSCLC patients is generally poor. During the last years, substantial progress has been made both in diagnosis and in treatment of this tumor. Meanwhile adjuvant therapy is established as standard therapy in early stages of NSCLC. Furthermore, effective and well tolerated drugs such as the EGFR inhibitor erlotinib (Tarceva  ) are now available in addition to chemotherapy, allowing for a target-oriented and specific elimination of tumor cells in metastatic NSCLC. Positron emission tomography (PET) is able to provide a more precise diagnosis of NSCLC than CT examinations. The PLUS trial showed that the number of futile thoracotomies could be roughly halved by using PET (approximately 41% with conventional staging versus 21% when using PET). Both PET and endoesophageal or endobronchial ultrasound now have been established as important procedures for restaging after radiochemotherapy or induction chemotherapy. The benefit of using platinum-based adjuvant chemotherapy in NSCLC of stage II and IIIA (operable) has been clearly illustrated by data from four large randomized trials. Compared with surgical procedures without adjuvant platinum-based chemotherapy, the survival rates could be improved by 10-15% in the different trials when administering additional platinum-based chemotherapy. Postsurgical radiation treatment reduced the locoregional relapse rate by about two thirds. However, many patients have to be excluded from adjuvant therapy because of their high age or comorbidities. Primary inoperable patients in the locally advanced stages IIIA/B require a multimodal procedure that should be defined by an interdisciplinary team of radiologists, pneumologists, and surgeons. The treatment-associated lethality of preoperative radiochemotherapy can be as high as 10%. In a meta-analysis carried out by the NSCLC Cooperative Group it was clearly shown that adjuvant platinum-based chemotherapy is superior to sole supportive therapy. The median survival time and the 1-year survival rate increases by approximately 8 weeks and 10%, respectively. Platinum-based chemotherapy therefore is established as standard treatment in patients with metastatic NSCLC (stage IV). Today, as many as 60% of all NSCLC patients with metastases already receive a second-line therapy in case of disease progress after first-line therapy. In addition to the traditional chemotherapeutic drugs docetaxel and pemetrexed, a low-molecular-weight inhibitor of the EGFR receptor tyrosine kinase, i. e. erlotinib (Tarceva  ), is now available for second-and third-line therapy, and it could be shown in phase III trials that the combination of these drugs resulted in 1-year survival rates of 30%. Moreover, the identification of predictive markers is desirable in order to be able to identify those patients who will benefit from chemotherapy or 'targeted therapy'. 
